Therapy News and Research

RSS

Medtronic initiates enrollment in Enlite Sensor study for diabetes

Medtronic, Inc. today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in adults with diabetes of its Enlite Sensor, the company's latest innovation in continuous glucose monitoring (CGM) technology for people with diabetes.

From Medtronic 10 Nov 2011

New epigenetic therapy may treat recurrent metastatic NSCLC

Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new epigenetic therapy may have potential in this population, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

10 Nov 2011

New genetic approach to treat fibrodysplasia ossificans progressiva

Scientists at Penn's Perelman School of Medicine Center for Research in FOP and Related Disorders have developed a new genetic approach to specifically block the damaged copy of the gene for a rare bone disease, while leaving the normal copy untouched.

9 Nov 2011

Fresenius Medical Care receives FDA clearance for 2008T hemodialysis delivery system

At the American Society of Nephrology's Kidney Week 2011, Fresenius Medical Care, the world's largest provider of dialysis products and services, announced that it received U.S. Food and Drug Administration 510 (K) clearance to extend improved touch screen navigation on its most advanced hemodialysis delivery system, the 2008T.

9 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Positive results from NeuroDerm's ND0611 Phase I/II study for advanced Parkinson's disease

NeuroDerm, Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet, Sinemet CR or Stalevo, in patients with advanced Parkinson's disease.

9 Nov 2011

Genetic sequencing key to fundamentally understanding diseases

What started back in 2004 as a three-person start-up may well be on its way to becoming a multi-million euro success story. Advanced by a team of young Dutch scientists pushing disruptive biotech innovations onto the market, the SME FlexGen is attracting the attention of some key investors and demonstrating the added value that public support can offer to innovative SMES, with the Eurostars funding programme leading the way.

9 Nov 2011

Treatments can help most HCM patients

Most of the 600,000 Americans with hypertrophic cardiomyopathy (HCM) -- a genetic heart muscle disease -- can live normal life spans, according to the first science-based guideline for diagnosing and treating this disorder.

9 Nov 2011

Protein p97/VCP aids DNA repair like a corkscrew

Human genetic material is constantly at risk of injury from the environment. Possible causes of damage include metabolic processes, chemical substances or ionizing radiation, such as X-radiation.

9 Nov 2011

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced data from a Phase II study of apremilast, its investigational oral immunomodulatory compound, in patients with ankylosing spondylitis (AS) were presented at the American College of Rheumatology Scientific Meeting in Chicago, IL.

9 Nov 2011

Benefits of hormone replacement therapy in protecting women from Alzheimer's inconclusive

A rigorous evaluation of the scientific literature reveals that the jury is still out when it comes to hormone replacement therapy and a woman's risk for Alzheimer's disease. Alzforum (http://www.alzforum.org) asked prominent scientists to analyze the results of published studies examining the effects of estrogen or estrogen-plus-progesterone therapy on women.

9 Nov 2011

Salix to acquire Oceana Therapeutics

Oceana Therapeutics LLC, a privately owned global company focused on commercializing best-in-class specialty therapeutics, today announced it has entered into a definitive agreement for the sale of its operating subsidiary, Oceana Therapeutics, Inc. to Salix Pharmaceuticals, Ltd. of Raleigh, NC.

9 Nov 2011

EI-IC bypass surgery does not lower risk of stroke recurrence in patients with TIA

A surgical procedure aimed at bypassing a blocked artery that supplies blood to the brain did not lower the subsequent stroke rate after 2 years in people who previously had a minor stroke, compared to those who did not have the surgery.

9 Nov 2011

Teenage girls with recurrent PID face fivefold risk of chronic pelvic pain and high rates of infertility

A study of the long-term consequences of pelvic inflammatory disease (PID) led by researchers at the Johns Hopkins Children's Center shows repeated bouts of the disease can double a woman's risk of infertility and quadruple her risk of chronic pelvic pain.

9 Nov 2011

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.

9 Nov 2011

Alliance HealthCare Services third quarter revenue increases 4.7% to $126.8 million

Alliance HealthCare Services, Inc., a leading national provider of outpatient diagnostic imaging and radiation therapy services, announced results for the third quarter ended September 30, 2011.

9 Nov 2011

Almac devises new test to detect likelihood of colon cancer recurring

Northern Ireland-based pharmaceutical development company Almac has devised a groundbreaking new test which can detect the likelihood of the recurrence of stage 2 colon cancer in patients who have undergone surgery.

9 Nov 2011

Micell announces preliminary data from MiStent Sirolimus DES clinical study

Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release.

9 Nov 2011

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Bristol-Myers Squibb Company today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events.

9 Nov 2011

Positive results from ChemoCentryx CCX354 Phase II study on RA

ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology.

9 Nov 2011

Therapy News and Research

Medtronic initiates enrollment in Enlite Sensor study for diabetes

New epigenetic therapy may treat recurrent metastatic NSCLC

New genetic approach to treat fibrodysplasia ossificans progressiva

Fresenius Medical Care receives FDA clearance for 2008T hemodialysis delivery system

Idera third quarter net loss increases to $5.5 million

Positive results from NeuroDerm's ND0611 Phase I/II study for advanced Parkinson's disease

Genetic sequencing key to fundamentally understanding diseases

Treatments can help most HCM patients

Protein p97/VCP aids DNA repair like a corkscrew

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Benefits of hormone replacement therapy in protecting women from Alzheimer's inconclusive

Salix to acquire Oceana Therapeutics

EI-IC bypass surgery does not lower risk of stroke recurrence in patients with TIA

Teenage girls with recurrent PID face fivefold risk of chronic pelvic pain and high rates of infertility

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Alliance HealthCare Services third quarter revenue increases 4.7% to $126.8 million

Almac devises new test to detect likelihood of colon cancer recurring

Micell announces preliminary data from MiStent Sirolimus DES clinical study

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Positive results from ChemoCentryx CCX354 Phase II study on RA

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News